For a modest 100-amino-acid protein, there are 10^130 possible sequences, while all life on Earth has only explored ~10^43. This vast, unexplored space means we can now design binders for "undruggable" targets that evolution never needed to create.
Instead of screening billions of nature's existing proteins (a search problem), AI-powered de novo design creates entirely new proteins for specific functions from scratch. This moves the paradigm from hoping to find a match to intentionally engineering the desired molecule.
Generative AI alone designs proteins that look correct on paper but often fail in the lab. DenovAI adds a physics layer to simulate molecular dynamics—the "jiggling and wiggling"—which weeds out false positives by modeling how proteins actually interact in the real world.
Traditional drug discovery separates finding a 'hit' from the long process of optimizing it into a drug candidate. DenovAI's 'one-shot' platform builds in advanced features from the start, collapsing a multi-year, disjointed process into a single, efficient design phase.
While AI is on the verge of cracking preclinical challenges, the biggest problem is the high drug failure rate in human trials. The next wave of innovation will use AI to design molecules for properties that predict human efficacy, addressing the fundamental reason drugs fail late-stage.
Backed by Aion Labs, a studio funded by competitors like Pfizer and Merck, DenovAI was co-created to solve a pre-validated industry challenge. This unique model provided deep R&D insights and a built-in customer base, ensuring its technology addressed real-world pharma needs from day one.